cefminox has been researched along with imipenem, anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanamori, M; Kirikae, T; Kitao, T; Miyoshi-Akiyama, T; Morita, K; Okazaki, M; Sekiguchi, J; Watanabe, N | 1 |
| Deguchi, K; Fukayama, S; Ishihara, R; Koguchi, M; Nakane, Y; Oda, S; Suzuki, Y; Yokota, N | 1 |
2 other study(ies) available for cefminox and imipenem, anhydrous
| Article | Year |
|---|---|
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
Topics: Amino Acid Sequence; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Citrobacter freundii; Conjugation, Genetic; DNA Primers; DNA, Bacterial; Enterobacteriaceae Infections; Escherichia coli K12; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Recombinant Proteins; Sequence Homology, Amino Acid | 2008 |
[Combined effects of arbekacin with other antibiotics against methicillin-resistant Staphylococcus aureus. II. The combined effect of arbekacin with imipenem or cefminox].
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephamycins; Dibekacin; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Imipenem; Methicillin Resistance; Staphylococcus aureus | 1992 |